Core Insights - Totus Medicines has appointed Simon Harnest as Chief Financial Officer, a strategic move as the company advances its clinical-stage program following positive results from its Phase 1 study of TOS-358, a covalent PI3Kα inhibitor [1][2] Company Overview - Totus Medicines specializes in small molecule drug discovery and development, utilizing a novel DNA-encoded covalent library technology combined with AI/ML, enabling the screening of hundreds of millions of drug candidates against multiple targets simultaneously [4] - The company is currently developing TOS-358, a covalent PI3Kα inhibitor, which is in a Phase 1 clinical trial, and is also working on other covalent inhibitors and has a drug discovery partnership with Lilly [4] Leadership and Experience - Simon Harnest brings over 15 years of experience in the biotech sector, having previously served as Chief Investment Officer at Metagenomi, where he led capital raises and the IPO process, contributing to over $1 billion in equity raised [3] - Harnest's prior roles include directing the US IPO and capital markets strategy at Cellectis and key positions at Trout Group and Trout Capital, focusing on investor relations in the life sciences industry [3]
Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial Officer